GoodRx Holdings (GDRX) Amortization of Deferred Charges (2019 - 2026)

GoodRx Holdings has disclosed Amortization of Deferred Charges across 8 years of filings, most recently posting $462000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $462000.0, up 7.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 13.88% YoY), and the FY2025 annual result was $1.8 million, down 29.2% from the prior year.
• Amortization of Deferred Charges came in at $462000.0 for Q1 2026 at GoodRx Holdings, up from $454000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $856000.0 in Q1 2022 to a low of $413000.0 in Q3 2024.
• The 5-year median for Amortization of Deferred Charges is $837000.0 (2024), against an average of $677764.7.
• Across the five-year window, Amortization of Deferred Charges slumped 51.07% in 2024 and increased 7.84% in 2025, its largest moves.
• GoodRx Holdings' Amortization of Deferred Charges stood at $851000.0 in 2022, then declined by 0.94% to $843000.0 in 2023, then tumbled by 50.06% to $421000.0 in 2024, then rose by 7.84% to $454000.0 in 2025, then climbed by 1.76% to $462000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $462000.0 (Q1 2026), $454000.0 (Q4 2025), and $445000.0 (Q3 2025), per Business Quant data.